Research Articles | Page 4 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes Jan 2021 American Journal of Hematology Myelodysplastic Syndromes (MDS)
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria Sep 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria Sep 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition Sep 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management Aug 2020 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study Jul 2023 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria Jun 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" Mar 2021 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond May 2023 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition Jun 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)